10:54 AM EDT, 10/08/2025 (MT Newswires) -- TransCode Therapeutics ( RNAZ ) said Wednesday it has agreed to buy biotechnology immuno-oncology company Polynoma from a subsidiary of CK Life Sciences.

The company also announced a $25 million equity investment from CK Life Sciences for the clinical development of TransCode's lead microRNA asset, TTX-MC138, into a phase 2 clinical study.

Under the deal to acquire Polynoma, TransCode said an indirect subsidiary of CK Life Sciences will receive 83,285 common shares and about 1,153 non-voting series A convertible preferred shares.

Under the financing deal, a subsidiary of CK Life Sciences purchased about 224 shares of non-voting series B convertible preferred stock for $20 million in cash and a $5 million promissory note in a private placement, the company said.

Both deals are likely to close Wednesday, TransCode said.

TransCode also said it named Chairman Philippe Calais as its chief executive officer, while Chief Financial Officer Tom Fitzgerald stepped down as interim CEO.

TransCode Therapeutics ( RNAZ ) shares were up more than 13% in recent Wednesday trading.

Price: 13.85, Change: +1.63, Percent Change: +13.30